27.89
Moderna Inc stock is traded at $27.89, with a volume of 2.98M.
It is down -0.59% in the last 24 hours and down -10.67% over the past month.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
See More
Previous Close:
$28.09
Open:
$28.15
24h Volume:
2.98M
Relative Volume:
0.29
Market Cap:
$10.85B
Revenue:
$3.14B
Net Income/Loss:
$-3.36B
P/E Ratio:
-3.1953
EPS:
-8.73
Net Cash Flow:
$-4.03B
1W Performance:
+8.83%
1M Performance:
-10.67%
6M Performance:
-22.21%
1Y Performance:
-68.96%
Moderna Inc Stock (MRNA) Company Profile
Name
Moderna Inc
Sector
Industry
Phone
(617) 714-6500
Address
325 BINNEY STREET, CAMBRIDGE
Compare MRNA with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
MRNA
Moderna Inc
|
27.89 | 10.90B | 3.14B | -3.36B | -4.03B | -8.73 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
394.19 | 100.71B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
577.43 | 61.52B | 14.21B | 4.46B | 3.56B | 39.68 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
458.97 | 58.84B | 2.46B | -319.09M | -52.09M | -2.47 |
![]()
ARGX
Argen X Se Adr
|
657.54 | 40.01B | 3.06B | 1.28B | 447.35M | 21.30 |
![]()
ONC
Beone Medicines Ltd Adr
|
315.28 | 38.20B | 3.81B | -644.79M | -669.77M | -6.24 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Mar-13-25 | Initiated | Citigroup | Neutral |
Feb-18-25 | Downgrade | Barclays | Overweight → Equal Weight |
Jan-29-25 | Downgrade | Goldman | Buy → Neutral |
Dec-18-24 | Downgrade | Argus | Buy → Hold |
Dec-10-24 | Resumed | BofA Securities | Underperform |
Nov-19-24 | Initiated | Berenberg | Hold |
Nov-18-24 | Upgrade | HSBC Securities | Hold → Buy |
Nov-15-24 | Initiated | Wolfe Research | Underperform |
Oct-17-24 | Initiated | Bernstein | Mkt Perform |
Sep-13-24 | Downgrade | JP Morgan | Neutral → Underweight |
Sep-13-24 | Downgrade | Jefferies | Buy → Hold |
Sep-13-24 | Downgrade | Oppenheimer | Outperform → Perform |
Aug-28-24 | Upgrade | HSBC Securities | Reduce → Hold |
Aug-07-24 | Upgrade | Deutsche Bank | Sell → Hold |
Aug-05-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
Feb-26-24 | Downgrade | HSBC Securities | Hold → Reduce |
Jan-02-24 | Upgrade | Oppenheimer | Perform → Outperform |
Nov-29-23 | Initiated | Canaccord Genuity | Hold |
Nov-03-23 | Upgrade | HSBC Securities | Reduce → Hold |
Nov-02-23 | Downgrade | Deutsche Bank | Hold → Sell |
Aug-04-23 | Downgrade | TD Cowen | Outperform → Market Perform |
Aug-03-23 | Downgrade | Deutsche Bank | Buy → Hold |
Jul-24-23 | Initiated | William Blair | Mkt Perform |
Jul-14-23 | Initiated | HSBC Securities | Reduce |
Jun-26-23 | Upgrade | UBS | Neutral → Buy |
Apr-26-23 | Initiated | Guggenheim | Neutral |
Mar-13-23 | Upgrade | TD Cowen | Market Perform → Outperform |
Mar-02-23 | Initiated | RBC Capital Mkts | Outperform |
Feb-24-23 | Downgrade | SVB Securities | Market Perform → Underperform |
Dec-19-22 | Upgrade | Jefferies | Hold → Buy |
Dec-14-22 | Downgrade | Chardan Capital Markets | Buy → Neutral |
Oct-21-22 | Upgrade | SVB Leerink | Underperform → Mkt Perform |
Sep-08-22 | Upgrade | Deutsche Bank | Hold → Buy |
Feb-01-22 | Upgrade | Redburn | Sell → Neutral |
Jan-26-22 | Upgrade | Deutsche Bank | Sell → Hold |
Jan-21-22 | Upgrade | BofA Securities | Underperform → Neutral |
Jan-21-22 | Initiated | UBS | Neutral |
Dec-07-21 | Initiated | Cowen | Market Perform |
Nov-09-21 | Initiated | Wolfe Research | Outperform |
Oct-22-21 | Initiated | Deutsche Bank | Sell |
Oct-15-21 | Upgrade | Piper Sandler | Neutral → Overweight |
Aug-06-21 | Downgrade | Oppenheimer | Outperform → Perform |
Aug-06-21 | Downgrade | Piper Sandler | Overweight → Neutral |
Jul-15-21 | Reiterated | Jefferies | Hold |
Feb-01-21 | Downgrade | BofA Securities | Neutral → Underperform |
Dec-16-20 | Downgrade | Jefferies | Buy → Hold |
Dec-16-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Dec-09-20 | Downgrade | Needham | Buy → Hold |
Nov-23-20 | Initiated | Wells Fargo | Equal Weight |
Nov-17-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
Sep-08-20 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
Jul-23-20 | Initiated | SVB Leerink | Mkt Perform |
Jul-20-20 | Downgrade | JP Morgan | Overweight → Neutral |
Jul-13-20 | Initiated | Jefferies | Buy |
Jun-30-20 | Initiated | Argus | Buy |
Jun-08-20 | Initiated | Barclays | Overweight |
Apr-30-20 | Initiated | BMO Capital Markets | Outperform |
Mar-05-20 | Downgrade | BofA/Merrill | Buy → Neutral |
Dec-03-19 | Resumed | BofA/Merrill | Buy |
Oct-25-19 | Initiated | ROTH Capital | Buy |
Apr-05-19 | Initiated | Chardan Capital Markets | Buy |
View All
Moderna Inc Stock (MRNA) Latest News
Pediatrics group defies CDC and recommends COVID shots for kids - Seeking Alpha
National Pension Service Decreases Stock Holdings in Moderna, Inc. $MRNA - MarketBeat
Invesco Ltd. Buys 877,162 Shares of Moderna, Inc. $MRNA - MarketBeat
Moderna Fails To Block UPC Claims Against Subsidiaries - Law360
mRNA Technology Market Is Booming So Rapidly | Pfizer, Moderna, BioNTech - openPR.com
Blair William & Co. IL Trims Stock Holdings in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Who Owns Moderna? Biggest Shareholders and Recent Insider Trades - TIKR.com
Charles Schwab Investment Management Inc. Grows Stock Holdings in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Moderna (NASDAQ:MRNA) Trading Up 6.6%Time to Buy? - MarketBeat
If You're in Your 30s, Consider Buying These 2 Healthcare Stocks - AOL.com
Neuberger Berman Group LLC Grows Stock Position in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Traders Buy High Volume of Moderna Call Options (NASDAQ:MRNA) - MarketBeat
Moderna's flu vaccine shows positive late-stage trial results, paving way for combination Covid shot - MSN
Stock Analysis | Moderna OutlookWeak Technicals and Mixed Market Signals - AInvest
Moderna Inc Expands Beyond Respiratory Vaccines – Is Diversification the Key to Long-Term Success? - Smartkarma
Moderna to lay off 10% of staff this year - MSN
Moderna Inc's GF Score Indicates Potential Underperformance - AInvest
Deutsche Bank AG Decreases Position in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Moderna Stock Surges 4.98% as Trading Volume Jumps 70% to 402nd Market Activity Rank - AInvest
A US FDA Move to Revoke Pfizer’s Pediatric COVID-19 Vaccine EUA Could Raise Supply Questions - insights.citeline.com
Moderna to Cut 10% of Staff to Offset Slowing Covid Business - MSN
Short bets on S&P 500 Healthcare sector ease in July; Moderna remains most heavily shorted stock - Seeking Alpha
Moderna layoffs: U.S. Pharma giant announces massive job cuts, to have less than 5,000 employees, MRNA stocks sink - MSN
Layoff Tracker: Bausch Health Closes California Site, Cuts 49 Employees - BioSpace
Vanguard Group Inc. Buys 72,763 Shares of Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
ASR Vermogensbeheer N.V. Invests $614,000 in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Mitsubishi UFJ Asset Management Co. Ltd. Raises Position in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Moderna’s SWOT analysis: mRNA pioneer faces pivotal year for stock By Investing.com - Investing.com Australia
Moderna’s SWOT analysis: mRNA pioneer faces pivotal year for stock - Investing.com
Rate Cut Rationale and Healthcare Gains: Evaluating the Surge in Biogen, Moderna, and Align Tech - AInvest
Biogen, Moderna, Align Technology, QuidelOrtho, and Masimo Shares Skyrocket, What You Need To Know - TradingView
Moderna Stock Jumps as NIH Chief Tempers Administration’s Attack on mRNA - Barron's
Notable Stocks Rise on August 13th: Paramount, Coinbase, Warner Bros., AMD, and Moderna Lead the Way. - AInvest
Is Moderna Stock A Sell After Cutting Its Sales Outlook — Again? - Investor's Business Daily
Multi Factor Analysis Ranks Moderna Inc. as Strong BuyShare Buyback & Free Safe Entry Trade Signal Reports - 선데이타임즈
UK Court of Appeal Confirms Moderna’s EP’949 Patent is Valid and Infringed by Pfizer/BioNTech - Democrat and Chronicle
3 Reasons to Avoid MRNA and 1 Stock to Buy Instead - Yahoo Finance
The 5 Most Interesting Analyst Questions From Moderna’s Q2 Earnings Call - Yahoo Finance
Other Nations Move Toward Making Their Own Vaccines as US Cuts Funding - Bloomberg.com
Moderna's COVID-19 Vaccine Faces Regulatory Threats, RSV Vaccine Sales Uncertain, and Clinical Programs in Development - AInvest
Moderna, Teleflex, Envista, Enovis, and UnitedHealth Shares Are Soaring, What You Need To Know - Yahoo Finance
CDC Shooting Linked To Suspect's COVID-19 Vaccine Beliefs, Former Staff Blame RFK Jr. Hostility Toward Agency - Benzinga
KDCA readies mRNA vaccines, tech for COVID-19, future outbreaks - BioWorld MedTech
FDA Weighs Pulling Pfizer’s Covid Vaccine for Kids Under Age 5 - Bloomberg.com
Moderna, Inc. (MRNA)’s “Got The Double Whammy,” Says Jim Cramer - MSN
Day 5 of Loss Streak for Moderna Stock with -7.9% Return (vs. -39% YTD) [8/11/2025] - Trefis
Moderna, Inc. (MRNA) stock price, news, quote and history - uk.finance.yahoo.com
FDA May Not Renew Pfizer's Authorization For Covid Shots In Younger Children, Moderna Prepares To Boost Supply - Benzinga
mRNA patent wars kick into higher gear during dog days of summer - JUVE Patent
Global and U.S. Personalized Cancer Vaccines Market Generated - openPR.com
Global Cancer Vaccines Market to Surpass USD 15.00 Billion by 2032, Unlocking Over USD 10 Billion in New Growth Opportunities | MarketsandMarkets™. - GlobeNewswire Inc.
Moderna Inc Stock (MRNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):